We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Digital Laparoscopic Platform Leverages Augmented Intelligence and Machine Learning

By HospiMedica International staff writers
Posted on 29 Jun 2022
Image: The Senhance surgical system with digital laparoscopy (Photo courtesy of Asensus Surgical)
Image: The Senhance surgical system with digital laparoscopy (Photo courtesy of Asensus Surgical)

Challenges in laparoscopic surgery can impact cost, utilization, effectiveness, and outcomes of the procedure. For instance, the inability of the surgeon to control vision can create efficiency and safety challenges. Quick movement or unsteady control of the camera can cause fogging, which requires a pause in the procedure for cleaning. Moreover, the limitations of traditional laparoscopy impact clinical intelligence, which is defined as point-of-care knowledge that allows a surgeon to make more informed decisions that may drive improved outcomes and procedural efficiency. Now, a first of its kind digital laparoscopic platform aims to eliminate the challenges and limitations of traditional laparoscopy by leveraging augmented intelligence to provide unmatched performance and patient outcomes through machine learning.

The Senhance Surgical System from Asensus Surgical, Inc. (Durham, NC, USA) is the first and only digital laparoscopic platform designed to support hospitals and surgeons by providing greater control in laparoscopy, reduce variability and increase OR efficiency. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, Senhance aims to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare.

Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit (ISU). The ISU enables machine vision-driven tools to gather data related to anatomical structures and control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field and allows a surgeon to change the visualized field of view using the movement of their instruments.

Asensus intends to unlock clinical intelligence and capabilities to reduce surgical variability and the complications associated with it by adding machine vision, augmented intelligence, and deep learning capabilities that will be built upon the digital library of data collected from surgeries performed using Senhance. The insights gained from these cases will help deliver on the promise of consistently superior surgery regardless of a surgeon’s experience or skill level by guiding improved decision making, enriching collaboration, and enhancing predictability.

Related Links:
Asensus Surgical, Inc. 

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Short Phlebotomy Cart
MSWA-3469-WHT
New
ow Frequency Pulse Massager
ET10 L

Channels

Critical Care

view channel
Image: Researchers have taken a major step toward cuff-free blood pressure monitoring (Photo courtesy of Gwyneth Moe/Boston University)

Cuff-Free Blood Pressure Monitoring Device to Improve Early Detection and Management of Hypertension

Hypertension affects nearly half of all adults in the U.S. and remains the leading cause of cardiovascular disease. Regular and accurate blood pressure monitoring is essential for managing this condition,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more